Lamb YN (2017) Inotuzumab ozogamicin: First global approval. Drugs 77(14):1603-1610. doi: 10.1007/s40265-017-0802-5 PMID: 28819740
Summary: Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody-calicheamicin conjugate, has received its first global approval as a promising treatment option. This novel therapy shows potential for addressing certain hematological malignancies and represents a significant advancement in the field of cancer treatment.